Terrence J. Bradley, MD, discusses the utility of ruxolitinib (Jakafi) in myelofibrosis and polycythemia vera.
Terrence J. Bradley, MD
Advertisement
Articles by Terrence J. Bradley, MD
Terrence J. Bradley, MD, discusses the challenges of treating patients with myeloproliferative neoplasms.
Terrence J. Bradley, MD, discusses the evolution of therapeutic strategies in myeloproliferative neoplasms.
Terrence J. Bradley, MD, assistant professor, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami in Health System, discusses the use of ruxolitinib (Jakafi) in the treatment of patients with myeloproliferative neoplasms (MPNs).
Advertisement
Latest Updated Articles
Dr. Bradley on Ruxolitinib in Myeloproliferative NeoplasmsMarch 29th 2019
Dr. Bradley on Evolving Therapeutic Strategies in MPNsApril 16th 2020
Dr. Bradley on the Challenges Faced in MPNsApril 24th 2020
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
5